Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. lowered its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 26.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 708,390 shares of the biotechnology company's stock after selling 254,659 shares during the period. Federated Hermes Inc. owned approximately 0.76% of Sarepta Therapeutics worth $68,310,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of SRPT. Vontobel Holding Ltd. boosted its holdings in shares of Sarepta Therapeutics by 12.8% in the fourth quarter. Vontobel Holding Ltd. now owns 25,278 shares of the biotechnology company's stock valued at $2,438,000 after acquiring an additional 2,863 shares in the last quarter. WCM Investment Management LLC purchased a new stake in Sarepta Therapeutics in the 4th quarter valued at approximately $600,000. Sapient Capital LLC acquired a new position in Sarepta Therapeutics during the 4th quarter worth approximately $978,000. Tobam raised its stake in shares of Sarepta Therapeutics by 4.8% during the 4th quarter. Tobam now owns 156,046 shares of the biotechnology company's stock worth $15,048,000 after buying an additional 7,105 shares in the last quarter. Finally, International Assets Investment Management LLC raised its stake in shares of Sarepta Therapeutics by 9,382.5% during the 4th quarter. International Assets Investment Management LLC now owns 11,379 shares of the biotechnology company's stock worth $1,097,000 after buying an additional 11,259 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. BMO Capital Markets began coverage on Sarepta Therapeutics in a report on Wednesday, January 31st. They issued an "outperform" rating and a $170.00 target price for the company. Evercore ISI raised their price objective on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an "in-line" rating in a research note on Tuesday, February 20th. Citigroup upped their target price on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a "buy" rating in a research report on Thursday, February 29th. Royal Bank of Canada increased their target price on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the company an "outperform" rating in a report on Thursday, February 29th. Finally, Wedbush restated an "outperform" rating and issued a $224.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $158.38.

Insider Buying and Selling

In related news, insider Bilal Arif sold 2,000 shares of the company's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the transaction, the insider now directly owns 26,836 shares in the company, valued at $3,457,550.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the company's stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the sale, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Bilal Arif sold 2,000 shares of Sarepta Therapeutics stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the transaction, the insider now directly owns 26,836 shares in the company, valued at $3,457,550.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,096 shares of company stock worth $2,739,419. 7.40% of the stock is owned by insiders.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT traded down $0.93 on Friday, hitting $115.62. The company had a trading volume of 641,078 shares, compared to its average volume of 985,430. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32. The company has a market cap of $10.86 billion, a PE ratio of -18.89 and a beta of 0.94. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $159.89. The business has a 50 day moving average of $126.52 and a 200 day moving average of $110.41.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.50. The company had revenue of $396.80 million for the quarter, compared to analyst estimates of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The firm's quarterly revenue was up 53.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.24) EPS. As a group, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.14 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.